Capital Performance Advisors LLP Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

Capital Performance Advisors LLP purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 350 shares of the company’s stock, valued at approximately $42,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of NVO. 1620 Investment Advisors Inc. bought a new stake in Novo Nordisk A/S during the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at $25,000. Orion Capital Management LLC purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth $26,000. Gilliland Jeter Wealth Management LLC raised its holdings in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares during the period. Finally, Halpern Financial Inc. lifted its position in Novo Nordisk A/S by 113.0% during the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Down 0.4 %

Shares of NVO opened at $107.20 on Monday. The business’s 50 day moving average is $121.42 and its 200 day moving average is $130.31. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The company has a market capitalization of $481.06 billion, a PE ratio of 34.69, a price-to-earnings-growth ratio of 1.48 and a beta of 0.42.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.